Charles Duncan

Charles C. Duncan is a Managing Director and senior biotechnology research analyst at Cantor Fitzgerald.123 He has over 25 years of sell-side experience in the biotechnology industry.1 Duncan joined Cantor Fitzgerald in July 2018 and is based in the United States.1

Career History

• Managing Director at Cantor Fitzgerald (July 2018 - Present)1
• Managing Director at Piper Jaffray (December 2012 - July 2018)1
• Managing Director & Senior Research Analyst at JMP Securities (November 2002 - December 2012)1

Prior to these roles, Duncan held analyst positions at various firms including Dresdner Kleinwort Wasserstein, Vector Healthcare Group - Prudential Securities, Tucker Anthony Cleary Gull, and Chatfield Dean & Co.1

Education and Qualifications

• PhD in Pharmaceutical Sciences, specializing in Neuropharmacology, from the University of Colorado at Boulder12
• Bachelor of Science in Zoology from the University of Wisconsin-Madison1
• Holds FINRA Series 87, 86, and 24 licenses1

Duncan has been recognized by industry sources, including the StarMine Analyst Awards, for his fundamental and timely analysis.1 He has also achieved a Tip Ranks ranking that places him in the top 5% of all analysts and above the majority of other senior biotech analysts.1